Monopar's ALXN1840 Phase 3 Data Shows Superior Neurologic Benefit in Wilson Disease, Bolstering Mid-2026 FDA NDA Plan
Summary
Monopar Therapeutics announced highly positive Phase 3 data for its lead candidate, ALXN1840, in Wilson disease patients with neurologic symptoms. The FoCus trial demonstrated statistically significant greater neurologic improvement and less worsening compared to standard of care, with durable benefits observed over multiple years. Specifically, ALXN1840 showed a 9% worsening rate versus 25% for standard of care (p=0.038) and a 45% improvement rate versus 32%. These robust results, coupled with a favorable safety profile, significantly de-risk the program and strongly support the company's planned New Drug Application (NDA) submission to the FDA in mid-2026. This is a major positive catalyst for Monopar, addressing a critical unmet need in a rare disease and potentially transforming the treatment landscape. Traders will now closely monitor the NDA submission and subsequent regulatory review process.
At the time of this announcement, MNPR was trading at $56.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $376.2M. The 52-week trading range was $28.40 to $105.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.